| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/03/2003 | WO2003053415A1 Pharmaceutical composition comprising skim milk powder |
| 07/03/2003 | WO2003053414A2 Triggered release from proteinoid microspheres |
| 07/03/2003 | WO2003053413A2 Sustained-release compositions |
| 07/03/2003 | WO2003053412A1 Stable granulates containing s-adenosylmethionne and process for the preparation thereof |
| 07/03/2003 | WO2003053411A1 Pulmonary delivery of aminoglycosides |
| 07/03/2003 | WO2003053410A1 Particulate compositions |
| 07/03/2003 | WO2003053409A1 Liposome composition for delivery of nucleic acid |
| 07/03/2003 | WO2003053408A1 Liposomal tumor necrosis factor compositions |
| 07/03/2003 | WO2003053407A1 Liposomal delivery of vitamin e based compounds |
| 07/03/2003 | WO2003053406A1 Fluorinated particles for inhalation & pharmaceutical formulation |
| 07/03/2003 | WO2003053405A1 Method and composition for dry eye treatment |
| 07/03/2003 | WO2003053404A1 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant |
| 07/03/2003 | WO2003053403A2 Pharmaceutical suspension for oral administration |
| 07/03/2003 | WO2003053402A1 Zero-order sustained released dosage forms and method of making the same |
| 07/03/2003 | WO2003053401A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| 07/03/2003 | WO2003053400A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | WO2003053399A2 Methods for wet granulating azithromycin |
| 07/03/2003 | WO2003053369A1 Allantoin-containing preparations for administration as gels and aerosols |
| 07/03/2003 | WO2003053365A2 Syn3 compositions and methods |
| 07/03/2003 | WO2003053357A2 Method and related composition employing nanostructures |
| 07/03/2003 | WO2003053350A2 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| 07/03/2003 | WO2003053336A2 Methods for the treatment of peripheral neural and vascular ailments |
| 07/03/2003 | WO2003053325A2 Microencapsulation of drugs by solvent exchange |
| 07/03/2003 | WO2003053292A1 Vaginal delivery of drugs |
| 07/03/2003 | WO2003053221A2 Methods using proton pump inhibitors |
| 07/03/2003 | WO2003053180A2 Undergarments containing active substances |
| 07/03/2003 | WO2003053158A2 Malleable protein matrix and uses thereof |
| 07/03/2003 | WO2003035136A3 System for administering a drug delivery device |
| 07/03/2003 | WO2003026767A3 Lysin-deficient bacteriophages having reduced immunogenicity |
| 07/03/2003 | WO2003026697A3 Organoleptically acceptable intraorally disintegrating compositions |
| 07/03/2003 | WO2003026611A3 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 07/03/2003 | WO2003013476B1 Compositions and methods to prevent abuse of opioids |
| 07/03/2003 | WO2003013440A3 Treatment and prevention of heat shock protein-associated diseases and conditions |
| 07/03/2003 | WO2003011204A3 Drug delivery systems |
| 07/03/2003 | WO2003005950A3 Pharmaceutical dispensing apparatus and method |
| 07/03/2003 | WO2002085338B1 Ipratropium formulation for pulmonary inhalation |
| 07/03/2003 | US20030125803 Stents/catheters for regrowth of endothelium |
| 07/03/2003 | US20030125800 Drug-delivery endovascular stent and method for treating restenosis |
| 07/03/2003 | US20030125714 Comprises inner compartments enclosed within semipermeable membrane coated with drugs; osmosis |
| 07/03/2003 | US20030125659 Dosage of transdermal delivery systems |
| 07/03/2003 | US20030125543 For addition to drugs as binder, disintegrant or excipient; bulk density; fluidized bed granulation |
| 07/03/2003 | US20030125517 Lipopeptides; virosomal delivery systems for transporting drugs, nucleic acids and proteins |
| 07/03/2003 | US20030125509 Indomethacin entrapped within polysaccaride (dextran) or proteins |
| 07/03/2003 | US20030125391 Pharmaceutical solutions of modafinil compounds |
| 07/03/2003 | US20030125388 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 07/03/2003 | US20030125387 Antioestrogens, capable of eliciting complete ablation of the trophic effects of oestrogens; cancer therapy |
| 07/03/2003 | US20030125385 Prepared by mixing gamma-hydroxybutyrate and a pH-adjusting agent in an aqueous medium |
| 07/03/2003 | US20030125376 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 07/03/2003 | US20030125351 Administering a heterocyclic amide compound to a glaucoma patient for inhibiting contraction of ciliary muscle; Rho kinase inhibitor |
| 07/03/2003 | US20030125350 Combination of formoterol and a tiotropium salt |
| 07/03/2003 | US20030125347 An oral dosage form containing an opiate and a capsaicinoid irritant, opiate is selected from codeine, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, oxycodone and their salts for the traeatment of drug abuse |
| 07/03/2003 | US20030125313 Prophylaxis/treatment of respiratory system disorders; administered by inhalation; potentiation; reversible airways obstruction, e.g., asthma, chronic obstructive pulmonary diseases (COPD) (e.g. bronchitis, emphysema); infections |
| 07/03/2003 | US20030125310 Combine solutions of each vitamin, i.e, K, D's, E and A, in water or an inert oil and emulsify using a protective colloid; drying; fineness; discoloration inhibition; homogeneity; oxidation resistance |
| 07/03/2003 | US20030125308 Antipruritic agents for external use |
| 07/03/2003 | US20030125307 Transdermally administering a preparation containing only acetylsalicylic acid as an active ingredient; bronchial asthma, allergic rhinitis, atopic dermatitis; eczema, lichen Vidal; insect stings; pruritis; side effect reduction |
| 07/03/2003 | US20030125302 Folic acid-polysaccharide complex, its preparation method and pharmaceutical composition containing the same as active component |
| 07/03/2003 | US20030125294 Selective toxin expression in angiogenic endothelial cells |
| 07/03/2003 | US20030125292 Synergistic stimulating immunoglobulin A (IgA) production by administering a nucleic acid encapsulated with a lipid and at least one antigen |
| 07/03/2003 | US20030125263 Nucleic acid ligand complexes |
| 07/03/2003 | US20030125252 Administering to a vertebrate an effective osteogenesis stimulating amount of an RAR (retinoic acid receptor) antagonist to treat both metabolic or non-metabolic diseases; RAR antisense oligonucleotide |
| 07/03/2003 | US20030125244 Endoparasiticidal agents |
| 07/03/2003 | US20030125238 Hemoglobin-based oxygen carriers are prepared by reacting hemoglobin with oxidatively ring-opened polysaccharides such as hydroxyethyl starch or dextran, and storing the resultant conjugate under conditions which allow it to transform to a |
| 07/03/2003 | US20030125237 Controlled release preparation of insulin and its method |
| 07/03/2003 | US20030125236 Phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the |
| 07/03/2003 | US20030124613 Epitope testing using soluble HLA |
| 07/03/2003 | US20030124368 Plurality of polyelectrolyte layers of alternating charge; hydrolytic degradation of a member of the polycationic layers, the polyanionic layers, and both. |
| 07/03/2003 | US20030124291 Film structures and methods of making film structures |
| 07/03/2003 | US20030124200 Sucralose, glucosamine and a beverage base, especially fruit juice; cartilage supplements include chondroitin, glucosamine, and hyaluronic acid |
| 07/03/2003 | US20030124197 Following surgery or injury, delivering to an external portion of said body passageway or cavity a therapeutic agent; include microtubule stabilizing agents, fibrosis inducers, angiogenic factors, growth factors and cytokines |
| 07/03/2003 | US20030124196 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 07/03/2003 | US20030124194 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
| 07/03/2003 | US20030124193 Atomizing nozzles include a liquid nozzle adapted to disperse a supply of liquid and a gas nozzle adapted to disperse a supply of gas; spray drying at a commercial plant scale. |
| 07/03/2003 | US20030124191 Pharmaceutical or nutraceutical, surfactant, wetting agent and diluent; rapid release when contacted with mucosal surface |
| 07/03/2003 | US20030124190 Methods and compositions for treating pain of the mucous membrane |
| 07/03/2003 | US20030124189 Combination of chitosan and second polymer that are not covalently or ionically crosslinked, prepared by dissolving both polymers in an acidic aqueous solution, dehydrating and recovering |
| 07/03/2003 | US20030124188 Oral pulsed dose drug delivery system |
| 07/03/2003 | US20030124187 Having reduced weight compared to existing formulations; common intermediate granulate comprising a fixed ratio of amoxycillin and clavulanate, with differing ratios in the final formulation |
| 07/03/2003 | US20030124186 Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| 07/03/2003 | US20030124185 Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
| 07/03/2003 | US20030124184 Liquiflash particles and an excipient mass; friability of less than 1%; need for conventional super disintegrant and having a friability of less than 1%; no need for conventional superdisintegrant |
| 07/03/2003 | US20030124183 Insert prepared by molding a flowable starting material embedded in a compressed dosage form that is coated with a thermal molded coating. |
| 07/03/2003 | US20030124182 Oral capsule formulation with increased physical stability |
| 07/03/2003 | US20030124181 Lipid carrier compositions with enhanced blood stability |
| 07/03/2003 | US20030124180 Liposomes containing active substances |
| 07/03/2003 | US20030124179 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder |
| 07/03/2003 | US20030124178 Soft, adherent, soluble oral patch |
| 07/03/2003 | US20030124177 Compositions and methods for transdermal oxybutynin therapy |
| 07/03/2003 | US20030124176 Use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. |
| 07/03/2003 | US20030124175 Adhesive polymer layer; removable protective layer; promotes the formation of dermis and collagen production. |
| 07/03/2003 | US20030124174 Method for treating non-neuropathic pain |
| 07/03/2003 | US20030124169 Biocompatible, biodegradable matrix and a protein, produced by expression of recombinant DNA capable of inducing endochondral bone formation in association with said matrix |
| 07/03/2003 | US20030124162 Pressing a sol phase of a solvent and gelling agent between liners; cooling to form a gel phase; and cutting the gel phase; free of a supporting substrate; large scale; drug, food and cosmetic delivery |
| 07/03/2003 | US20030124160 Targeted drug delivery |
| 07/03/2003 | US20030124151 Pamidronate solution |
| 07/03/2003 | US20030124149 Bioactive absorbable microparticles as therapeutic vaccines |
| 07/03/2003 | US20030124139 Reduced aggregation and proteolytic breakdown; dissolution buffer comprising at least one amorphous excipient, at least one amorphous buffer, and at least one MenC immunogen |
| 07/03/2003 | US20030124119 Antibody is dissolved in a buffer solution containing as a buffer acetic acid, citric acid, phosphoric acid, and/or salts thereof and is a solution of pH 5 to 8. |
| 07/03/2003 | US20030124112 Containing lysozyme, tris(hydroxymethyl)aminomethane, and optionally ascorbic acid, and/or citric acid and/or ethylenediaminetetraacetic acid |
| 07/03/2003 | US20030124088 Preparation for preventing bile acid diarrhea |
| 07/03/2003 | US20030124063 Premeasured single unit dose; may be free of anti-microbial preservatives, such as benzalkonium chloride. |